Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Gray Private Wealth LLC

Gray Private Wealth LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 715 shares of the medical research company’s stock after selling 42 shares during the period. Thermo Fisher Scientific makes up approximately 0.3% of Gray Private Wealth LLC’s portfolio, making the stock its 22nd biggest holding. Gray Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $395,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Beaumont Financial Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.8% during the 1st quarter. Beaumont Financial Advisors LLC now owns 2,199 shares of the medical research company’s stock valued at $1,278,000 after buying an additional 17 shares during the last quarter. Cedar Wealth Management LLC grew its position in Thermo Fisher Scientific by 14.5% in the first quarter. Cedar Wealth Management LLC now owns 134 shares of the medical research company’s stock worth $78,000 after acquiring an additional 17 shares in the last quarter. Patrick M Sweeney & Associates Inc. raised its holdings in shares of Thermo Fisher Scientific by 1.8% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,031 shares of the medical research company’s stock valued at $570,000 after purchasing an additional 18 shares in the last quarter. Quent Capital LLC boosted its holdings in Thermo Fisher Scientific by 1.0% in the second quarter. Quent Capital LLC now owns 1,886 shares of the medical research company’s stock worth $1,043,000 after purchasing an additional 19 shares in the last quarter. Finally, Prentice Wealth Management LLC raised its holdings in Thermo Fisher Scientific by 2.1% during the second quarter. Prentice Wealth Management LLC now owns 913 shares of the medical research company’s stock valued at $505,000 after buying an additional 19 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $1,201,700.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,860,920.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the completion of the sale, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,860,920.55. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Lisa P. Britt sold 3,624 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the transaction, the vice president now directly owns 13,699 shares in the company, valued at $8,397,760.98. The disclosure for this sale can be found here. Insiders sold 33,084 shares of company stock valued at $19,767,092 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $6.31 during mid-day trading on Thursday, reaching $603.86. The company had a trading volume of 1,137,273 shares, compared to its average volume of 1,535,194. The company’s 50-day moving average is $572.85 and its 200-day moving average is $573.13. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. The company has a market capitalization of $230.67 billion, a P/E ratio of 38.70, a P/E/G ratio of 2.81 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $622.30.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business’s revenue was down 1.4% on a year-over-year basis. During the same period last year, the business earned $5.15 earnings per share. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on TMO shares. Stifel Nicolaus raised their price objective on Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Barclays lowered their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Robert W. Baird increased their target price on Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Finally, Royal Bank of Canada upped their price target on Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $618.94.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.